Pola Penggunaan Antidiabetes–antihipertensi Dan Potensi Interaksi Obat Pada Pasien Diabetes Melitus Tipe 2 Dengan Hipertensi: Studi Retrospektif Di Rsud Sultan Suriansyah Banjarmasin

This is the authors' abstract. We don't add key points for this paper.

The concurrent treatment of type 2 diabetes mellitus (T2DM) and hypertension often involves multiple medicines, making potential drug–drug interactions an important safety consideration. To describe antidiabetic and antihypertensive prescribing patterns, identify potential drug interactions, and assess their associations with patient and treatment characteristics. This retrospective, cross-sectional descriptive–analytic study reviewed 180 inpatient medical records from Sultan Suriansyah Regional General Hospital, Banjarmasin, covering December 2024 to July 2025. Records were selected through purposive sampling. Descriptive statistics and chi-square or Fisher’s exact tests were applied as appropriate. Levemir FlexPen accounted for 95 of 294 documented antidiabetic uses (32.3%), while amlodipine accounted for 128 of 368 antihypertensive uses (34.8%). Potential drug interactions were identified in 129 of 180 records (71.7%). Among 231 potential interaction pairs, 220 (95.2%) were pharmacodynamic and 219 (94.8%) were classified as moderate. Medication count was significantly associated with potential interactions (p = 0.007; OR = 0.072; 95% CI = 0.008–0.632). Potential drug interactions were identified in most records. Among the assessed factors, the number of medications showed a statistically significant association with potential interactions.